Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.
Back to dashboard
Company Information
About this company
Key people
Richard J. Hawkins
Independent Chairman of the Board
Marc H. Hedrick
President, Chief Executive Officer, Director
Andrew Sims
Chief Financial Officer
Eric J. Daniels
Chief Development Officer
Ronald A. Andrews
Independent Director
Howard Clowes
Independent Director
Kyle Guse
Independent Director
Annigje van Es-Johansson
Independent Director
Click to see more
Key facts
- Shares in issue7.60m
- EPICCNSY
- ISINUS72941H8060
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$22.47m
- Employees28
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.